Virtual MSOC 2021

Virtual Medical Special Operations Conference®


Online training

Save the Date May 18-20, 2021

Virtual Medical Special Operations Conference® 2021

The Medical Special Operations Conference® (MSOC) continues to collaborate with the State Urban Search and Rescue (SUSAR) Alliance, and Federal partners to host a revolutionary virtual conference and training experience. This event will bring together first responders, stake holders, and policy makers from around the globe.

The virtual MSOC and training event will be hosted online May 18-20, 2021.

Registration will open soon!!

The MSOC continues to innovate and raise the bar for military, federal, state, and local responders who attend to share their experiences, best practices, and ideas. As with prior events, MSOC will include current hot topics, latest medical technological updates, and recent case studies from around the world. Additionally, Continuing Education Units (CEU) are available to paramedics, nurses, physician assistants, and physicians who attend.  This virtual online event will also include participation and instruction from subject matter experts transmitting live from their home territories.

Follow Us:


Thank you to all essential workers and first responders

2020 Medical Special Operations Conference

November 8 - 12, 2020



Annual Medical Special Operations Conference®

November 8 - 12, 2020

The Medical Special Operations Community, is proud to invite all first responders, to this year’s official Medical Special Operations Conference​® (MSOC). This year, MSOC has partnered with the State Urban Search and Rescue (SUSAR) Alliance, and together will host their respective conferences from November 8 – 12 in Columbia, South Carolina. 

The MSOC continues to be the conference that military, federal, state and local medical responders attend to share their experiences, best practices, and ideas.  Each year MSOC continues to evolve to include current hot topics, latest medical technological updates, and recent case studies from around the world.  Continuing Education Units (CEU) are available to paramedics, nurses, physician assistants and physicians.


This year, MSOC has partnered with the State Urban Search and Rescue (SUSAR) Alliance, and together will host their respective conferences November 18–21, 2019 in Wichita, Kansas. Don’t miss this opportunity to learn, network, and exchange ideas with rescue and medical professionals, leading industry equipment experts, along with other stake holders from across the country.

Countdown to MSOC 2019
Host Conference Hotel


Located at:

To be determined


Group Info: To be determined

Food and Transportation
  • Free Hot Breakfast – Start every day with make-your-own Belgian waffles, scrambled eggs, sausage, fresh fruit, oatmeal, biscuits and gravy, KELSO+BROS® coffee and more. Free hot breakfast is served daily from 6–9:30 a.m. on weekdays and 7–10 a.m. on weekends.

  • Free 5:30 Kickback®* – Join us from 5:30–7 p.m. every evening to enjoy free hot food and cold beverages at our 5:30 Kickback®. We feature a rotating menu of hot food, beer, wine, mixed drinks and soft drinks.

  • Free Wi-Fi Throughout the Hotel – Get the score, check your social networks or email family members from anywhere in the hotel – for free!

More information will be posted soon

Classes will be held at the Drury Plaza Hotel, Wichita Fire Department Training Center, and other locations to be announced.

For general information, please call 239-203-9331 or email

To become an exhibitor, please call 239-203-9331 ​or email

MSOC Schedule (click tabs to view)
MSOC Conference Information

Participants may register by filling out the online registration form and pay by credit card or by purchase order (must contact us via email at for purchase order).

Tickets may only be purchased through the MSOC registration process. Two day courses space is limited and are available on a first-come, first-served basis.

Participants will receive proof of registration and MSOC identification that will be used as security measures during MSOC activities.  Participants must wear MSOC identification and may be asked to provide a valid picture ID as proof of registration.

Cancellation must be received in writing via email to no later than October 12, 2019. Full refunds less a $100 processing fee will be issued for cancellations received by the above date.  Any cancellation request  received later than this date will be subject to review.

MSOC Transportation will be provided – logistics will be posted here SOON.

What if i have to cancel my stay?

You can cancel until 12 pm on the day of your arrival with no charge unless otherwise stated. Cancelling your reservation after this deadline or failing to show will result in a non-refundable charge for 1 night per room to your credit card. Taxes may apply.
go to for more information.


Wichita Dwight D. Eisenhower National Airport
2277 Eisenhower Airport Parkway, Wichita, KS 67209

Continuing Medical Units (CEU) / Continuing Medical Education credit will be provided.  Participants must sign in daily to receive credit.

Prisma Health develops FDA-authorized 3D-printed device that lets a single ventilator treat four patients

The impending shortage of ventilators for U.S. hospitals is likely already a crisis, but will become even more dire as the number grows of patients with COVID-19 that are suffering from severe symptoms and require hospitalization. That’s why a simple piece of hardware newly approved by the FDA for emergency use — and available free via source code and 3D printing for hospitals — might be a key ingredient in helping minimize the strain on front-line response efforts.

 The Prisma Health VESper is a deceptively simple-looking three-way connector that expands use of one ventilator to treat up to four patients simultaneously. The device is made for use with ventilators that comply to existing ISO standard ventilator hardware and tubing, and allows use of filtering equipment to block any possible transmission of viruses and bacteria.

VESper works in device pairs, with one attached to the intake of the ventilator, and another attached to the return. They also can be stacked to allow for treatment of up to four patients at once — provided the patients require the same clinical treatment in terms of oxygenation, including the oxygen mix as well as the air pressure and other factors.

This was devised by Dr. Sarah Farris, an emergency room doctor, who shared the concept with her husband Ryan Farris, a software engineer who developed the initial prototype design for 3D printing. Prisma Health is making the VESper available upon request via its printing specifications, but it should be noted that the emergency use authorization under which the FDA approved its use means that this is only intended effectively as a last-resort measure — for institutions where ventilators approved under established FDA rules have already been exhausted, and no other supply or alternative is available in order to preserve the life of patients.

Devices cleared under FDA Emergency Use Authorization (EUA) like this one are fully understood to be prototypes, and the conditions of their use includes a duty to report the results of how they perform in practice. This data contributes to the ongoing investigation of their effectiveness, and to further development and refinement of their design in order to maximize their safety and efficacy.

In addition to offering the plans for in-house 3D printing, Prisma Health has sourced donations to help print units for healthcare facilities that don’t have access to their own 3D printers. The first batch of these will be funded by a donation from the Sargent Foundation of South Carolina, but Prisma Health is seeking additional donations to fund continued research as well as additional production.

New York will be first state to test treatment of coronavirus with blood from recovered patients

Mike Hixenbaugh
March 24

Hoping to stem the toll of the state’s surging coronavirus outbreak, New York health officials plan to begin collecting plasma from people who have recovered and injecting the antibody-rich fluid into patients still fighting the virus.

Gov. Andrew Cuomo announced the plans during a news briefing Monday. The treatment, known as convalescent plasma, dates back centuries and was used during the flu epidemic of 1918 — in an era before modern vaccines and antiviral drugs.


Some experts say the treatment, although somewhat primitive, might be the best hope for combating the coronavirus until more sophisticated therapies can be developed, which could take several months.


“There have been tests that show when a person is injected with the antibodies, that then stimulates and promotes their immune system against that disease,” Cuomo said. “It’s only a trial. It’s a trial for people who are in serious condition, but the New York State Department of Health has been working on this with some of New York’s best health care agencies, and we think it shows promise, and we’re going to be starting that this week.”

New York has seen a dramatic rise in coronavirus cases in recent days, with about 20,000 confirmed cases and more than 150 deaths as of Monday afternoon, more than in any other state.

State health officials said they expect to get approval from the Food and Drug Administration to begin the plasma trial in the coming days. A spokesman for the FDA confirmed to NBC News that the agency is “working expeditiously to facilitate the development and availability” of convalescent plasma. And at a White House briefing last week, FDA Commissioner Stephen Hahn singled out the treatment as a promising option to fight the disease in the near term.

“That’s great news,” said Dr. Arturo Casadevall, an infectious disease expert at the Johns Hopkins Bloomberg School of Public Health, who has been calling for widespread use of convalescent plasma. “When we started talking about this a few weeks ago, it was just an idea, and now it seems it’s going to become a reality.”


The method — essentially harvesting virus-fighting antibodies from the blood of previously infected patients — dates back more than a century, but it has not been used widely in the United States in decades. Infusions of convalescent plasma were associated with milder symptoms and shorter hospital stays for some patients during the 2002 SARS outbreak, and initial reports from China suggest convalescent plasma might also be effective in dulling the effects of COVID-19, the disease caused by the coronavirus.

The treatment is not without risks. There is danger in giving a patient the wrong type of blood or inadvertently transmitting other pathogens in a transfusion, but safety advancements over the past two decades have made adverse outcomes rare.

In New York, health officials said they plan to begin recruiting patients who have fully recovered from COVID-19 in the coming days. That effort, officials said, would likely start in New Rochelle, the New York City suburb that was the center of the state’s initial outbreak a few weeks ago, because of the concentration of people there who have already recovered.

Potential donors would first need to undergo tests to ensure that they are no longer contagious and to confirm that their blood contains the antibodies needed to fight the disease, state health officials said. After that, donors would go to a local blood bank to give plasma — the liquid part of blood left once cells and platelets have been removed — although the state is still working out logistical details.

New York will begin by offering the treatment only to critically ill patients. But, experts said, once it is proven safe and effective, the treatment will likely work best if given to patients before symptoms become too severe. Casadevall said past studies indicate that proactive infusions of convalescent plasma might also be effective in protecting front-line health care workers from becoming seriously ill.

Similar efforts are underway across the country as hospitals scramble to prepare for an onslaught of critically ill COVID-19 patients, similar to what’s happened in New York and Seattle.

Download the NBC News app for full coverage of the coronavirus outbreak

Doctors from nearly two dozen hospitals have joined the Johns Hopkins-led effort, Casadevall said, including researchers at the Mayo Clinic in Minnesota, the Stanford University Medical Center in California and the Albert Einstein College of Medicine in New York. The researchers have been in contact with the FDA through the weekend, he said, and they hope to launch clinical trials similar to the one in New York in the coming weeks.

Michael Felberbaum, an FDA spokesman, said the agency could not comment on specific COVID-19 clinical trials. But he confirmed that the agency was working to facilitate the use of convalescent plasma.

“The agency is actively engaging with researchers to discuss the possibility of collaboration on the development of a master protocol for the use of convalescent plasma, with the goal of reducing duplicative efforts,” Felberbaum said.



COVID 19 News

Prisma Health develops FDA-authorized 3D-printed device that lets a single ventilator treat four patients
New York will be first state to test treatment of coronavirus with blood from recovered patients
US Military Scientists Hope To Have Coronavirus Therapeutic By Summer
Death toll rises to 22 after powerful tornadoes tear through Tennessee
DOD makes plans to combat coronavirus
[covid19-ultimate-videos col-sm="2" col-lg="3"]

US Military Scientists Hope To Have Coronavirus Therapeutic By Summer

March 10 




A new approach would use RNA or DNA to help the body develop antibodies to the rapidly spreading illness.

A U.S. military research program that seeks a new way to boost a body’s immunity to viruses could change how governments and militaries prepare for pandemics — and might even arrive soon enough to help with the COVID-19 outbreak.

DARPA’s Pandemic Prevention Platform isn’t looking to create a vaccine, which can take years to produce and weeks to take effect in the body. Rather, the goal is to identify the specific monoclonal antibodies that the body naturally produces when it encounters a virus, and then trick the body into producing the one that guards against a specific illness. That could serve as a temporary, months-long shield that can protect the individual from the pathogen until a vaccine can be brought online.

But these antibodies “take a long time to find and discover. There’s a long pipeline in the biomedical world to identify and test them and really understand these antibodies,” said Dr. Amy Jenkins, who manages the program at DARPA.

One of the goals of the program is to accelerate the discovery process.

“We have really trimmed that timeline down from what is usually multiyear timeline to just being a several week timeline,” Jenkins said on Monday. 

It’s a feat they’ve achieved through investments in microfluidics, the manipulation of liquids at the sub-millimeter range; nanofabrication, the fabrication of objects less than a billionth of a meter in size; and new approaches to gene sequencing. 

Jenkins described it this way: “We are able to take a patient that has recovered from this pathogen, for example, and we are able to sequence many of of their B cells. So those cells that make those antibodies that help protect you against those pathogens? We are now able to sequence all of those because of next-generation sequencing approaches.”


But they have very little of the B-cell sample to work from: just one sample from a single individual. If that person’s antibody response was relatively weak, there will be less antibody material to find. “We are relying on that one patient’s immune response. We would typically do this for anywhere between five and ten patients. We have one. So if that one person had a really robust immune response, that’s going to be great. If they didn’t because some people just respond differently, we could be in trouble, because it may be hard to find an antibody. Preliminary data suggests that there may be antibodies present. We are optimistic but also cautious that the antibodies are there,” she said. 

The second goal is to accelerate the delivery of manufactured antibodies. Like vaccines, antibodies are produced in bioreactors, basically a giant, complex cell culture that plays the role of the human body. 

Jenkins and her collaborators are trying to invent a new way to produce antibodies at scale by using the RNA and DNA code of those COVID-19. When that RDA or DNA is injected into a patient, it would begin to work immediately, helping health people ward off the virus and perhaps even functioning to treat sick people as well.

It’s the difference between buying a piece of furniture already assembled versus a mail-order kit with an instruction manual. The hope is that the body will be able to construct the response itself. In essence, said Jenkins, the body becomes the bioreactor. Since RNA and DNA is much easier to produce than a traditional vaccine, the hope is to drastically cut down on the time to manufacture.